Search

Zai Lab Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

24.74 0.73

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.15

Max

24.98

Pagrindiniai rodikliai

By Trading Economics

Pajamos

191K

-51M

Pardavimai

6.7M

106M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-47.808

Darbuotojai

1,784

EBITDA

-2.1M

-46M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+60.02% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

892M

2.9B

Ankstesnė atidarymo kaina

24.01

Ankstesnė uždarymo kaina

24.74

Naujienos nuotaikos

By Acuity

38%

62%

77 / 339 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-14 23:51; UTC

News

Rimini Street shares lower in after-market trading despite announcing a partnership with Datacom to support Oracle and SAP software in Australia and New Zealand.

2026-09-14 23:51; UTC

News

Shares of Gartner Inc are lower in after-market hours following unusual weakness, despite the recent launch of its IT Symposium/Xpo conference highlighting key technology trends.

2026-09-14 23:41; UTC

News

Autodesk shares are lower in after-market hours following a Neutral rating from Cantor Fitzgerald, which set a price target of $215.00.

2026-09-14 23:36; UTC

Correlated Moves
News

ATI Inc will highlight aerospace opportunities at the Morgan Stanley Laguna Conference on September 17, 2026. Shares were higher in after-market trading.

2026-09-14 23:36; UTC

News

NextEra Energy plans to enhance its merger proposal with Dominion Energy by extending bill credits and creating 600 new jobs in Virginia. Shares rose in after-market hours.

2026-09-14 23:31; UTC

News

Northrop Grumman Corp received a $34,388,301 contract modification for military helicopter components. Shares declined in after-market trading despite the news.

2026-09-14 23:31; UTC

News
Social Media

Lockheed Martin secured over $1.3 billion in defense contracts from the U.S. Department of War, with shares trading higher in after-market hours.

2026-09-14 23:31; UTC

News
Social Media

Scholar Rock Holding Corp shares declined in after-market trading following FDA approval of Isembyld, amid concerns over pricing and treatment risks.

2026-09-14 23:26; UTC

Correlated Moves
News

NXP Semiconductors NV gains in after-market trading, supported by its focus on physical AI and a shift to asset-light manufacturing for automotive revenue.

2026-09-14 23:21; UTC

Event
News

Children's Place reported second-quarter net sales of $241.8 million, missing estimates, and shares fell sharply in after-hours trading following the results.

2026-09-14 23:21; UTC

Correlated Moves
News

The U.S. dollar strengthens against major currencies, boosting USD/DKK amid expectations of a Fed interest rate hike following higher inflation figures.

2026-09-14 23:16; UTC

News

Walt Disney Co is requiring more remote employees to return to the office four days a week. Shares are little changed in after-market trading.

2026-09-14 23:11; UTC

News

Leonardo DRS rises in after-market on Guggenheim Buy rating.

2026-09-14 23:11; UTC

Correlated Moves
News

The U.S. dollar strengthens against major currencies, including USD/CZK, amid expectations of a Federal Reserve interest rate hike following rising inflation.

2026-09-14 23:06; UTC

Correlated Moves
News

Morgan Stanley's shares are advancing in after-market trading, influenced by Goldman Sachs' performance amid rising crude oil prices and supply concerns.

2026-09-14 23:06; UTC

News

Uranium Energy Corp shares are lower in after-market hours amid rising crude oil prices and concerns over future uranium supply dynamics from Saudi Arabia's recent discoveries.

2026-09-14 23:06; UTC

News

Marathon Petroleum shares are higher in after-market trading following recognition at the Fleet Safety Awards, reflecting positive sentiment amid global fuel supply constraints.

2026-09-14 23:06; UTC

News
Social Media

Eli Lilly's Foundayo captures over 30% of new U.S. obesity patients, boosting shares higher in after-market hours amid strong demand for oral treatments.

2026-09-14 23:06; UTC

News

NVIDIA shares are higher in after-hours trading following President Trump's remarks dismissing AI regulation concerns during a call with CEO Jensen Huang.

2026-09-14 23:06; UTC

News

Target Corp appointed Mark Weinstein as Chief Marketing and Guest Experience Officer, a move aimed at enhancing consumer engagement. Shares are trading higher in after-market hours.

2026-09-14 23:06; UTC

News

Accenture PLC shares are lower in after-market hours following a $25 million settlement over discrimination claims. Broader market pressures also weigh on the stock.

2026-09-14 23:06; UTC

News

Ethereum is trading higher amid positive market sentiment and rising crude oil prices. The Federal Reserve's expected interest rate hike adds complexity to the market.

2026-09-14 23:06; UTC

News

Bitcoin is trading higher amid rising crude oil prices and inflation concerns. U.S. Treasury yields reaching 5% also impact investor sentiment towards the digital asset.

2026-09-14 23:06; UTC

News

Ethereum is trading higher amid positive sentiment, despite intraday volatility. Crude oil price surges and upcoming Fed rate hike add complexity to market dynamics.

2026-09-14 23:06; UTC

News

Bitcoin is trading higher amid rising crude oil prices and heightened inflation concerns. U.S. Treasury yields have also reached 5%, impacting investor sentiment.

2026-09-14 23:01; UTC

News

BlackRock shares are rising in after-market trading following CEO Larry Fink's participation in a summit aimed at attracting C$1 trillion in global investments to Canada.

2026-09-14 23:01; UTC

News

Dave and Buster's Entertainment shares fell after the company reported a $12.5 million net loss and revenue that missed expectations during after-market hours.

2026-09-14 23:01; UTC

News

Radiant Logistics reports fourth-quarter revenue of $261.4 million, an 18.5% increase, and net income of $7.5 million, driving shares higher in after-market trading.

2026-09-14 23:01; UTC

News

Leidos Holdings has secured an $875 million Navy contract for network management, boosting shares in after-market hours.

2026-09-14 23:01; UTC

Event
News

Enova International withdrew its acquisition applications for Grasshopper Bancorp, leading shares lower in after-market hours. The company reaffirmed its guidance for 2026.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

60.02% į viršų

12 mėnesių prognozė

Vidutinis 39.333 USD  60.02%

Aukščiausias 45 USD

Žemiausias 36 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

77 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat